A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Complete Title: A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Trial Phase: I/II
Investigator: Mazyar Shadman
Study consists of two main parts to explore BGB-16673 recommended dosing, a Part 1 monotherapy dose finding comprised of monotherapy dose escalation and monotherapy safety expansion of selected doses, and a part 2 (dose expansion cohorts)
Leukemia, Chronic Lymphocytic (CLL)
Lymphoma, Small Lymphocytic (SLL)
Lymphoma, Large B-Cell, Diffuse
Lymphoma, B-Cell Non-Hodgkin
Lymphoma, Marginal Zone
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies